Show simple item record

dc.contributor.advisorHaley, Roberten
dc.creatorNettune, Gregoryen
dc.date.accessioned2010-07-12T16:19:02Zen
dc.date.available2010-07-12T16:19:02Zen
dc.date.issued2006-10-13en
dc.identifier.other77080747en
dc.identifier.urihttp://hdl.handle.net/2152.5/214en
dc.description.abstractPurpose: Age-related macular degeneration (ARMD) is a leading cause of irreversible blindness in the industrialized world. Studies suggest that HMG CoA reductase inhibitors (statins) might slow the progression of dry ARMD to the exudative stage. We set out to determine if statin use reduces the risk of progression to exudative ARMD in a matched case-control study. Methods: An epidemiological study of 61 cases with exudative ARMD matched by age, gender, and race to 61 controls with early, high-risk ARMD determined by prospective ophthalmologic examination. Results: The risk of exudative ARMD was increased by smoking within the past 20 years (OR=5.8, 95% CI 1.42-23.77) and reduced by use of statins (OR=0.2, 95% CI 0.04-0.93). Further, the duration of statin use up to four years was associated with an increasing degree of protection (9% reduction each month, 95% CI 0.85-0.98). Conclusion: Statin use may reduce the progression from dry to exudative ARMD.en
dc.format.mediumElectronicen
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.subjectMacular Degenerationen
dc.subjectBlindnessen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitorsen
dc.titleProtective Effect of Statin Use in the Progression of Dry to Exudative Age-Related Macular Degenerationen
dc.type.materialTexten
dc.type.genredissertationen
dc.format.digitalOriginborn digitalen
thesis.degree.grantorSouthwestern Medical Schoolen
thesis.degree.nameM.D. with Distinctionen
thesis.degree.levelDoctoralen
thesis.degree.disciplineResearchen
thesis.date.available2007-10-13en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record